| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.
|
Nat Biotechnol
|
2008
|
5.54
|
|
2
|
Blocking neuropilin-1 function has an additive effect with anti-VEGF to inhibit tumor growth.
|
Cancer Cell
|
2007
|
4.11
|
|
3
|
Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site.
|
Science
|
2009
|
3.87
|
|
4
|
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib.
|
Cancer Res
|
2006
|
3.34
|
|
5
|
MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival.
|
Cancer Res
|
2008
|
2.33
|
|
6
|
An Fcγ receptor-dependent mechanism drives antibody-mediated target-receptor signaling in cancer cells.
|
Cancer Cell
|
2011
|
2.14
|
|
7
|
Effects of anti-VEGF on pharmacokinetics, biodistribution, and tumor penetration of trastuzumab in a preclinical breast cancer model.
|
Mol Cancer Ther
|
2012
|
2.03
|
|
8
|
Antibody-based targeting of FGFR3 in bladder carcinoma and t(4;14)-positive multiple myeloma in mice.
|
J Clin Invest
|
2009
|
1.89
|
|
9
|
Identification and immunotherapeutic targeting of antigens induced by chemotherapy.
|
Nat Biotechnol
|
2006
|
1.68
|
|
10
|
Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent.
|
Cancer Res
|
2007
|
1.59
|
|
11
|
Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging.
|
Clin Cancer Res
|
2009
|
1.56
|
|
12
|
Antibody-drug conjugates for the treatment of non-Hodgkin's lymphoma: target and linker-drug selection.
|
Cancer Res
|
2009
|
1.41
|
|
13
|
Hath1, down-regulated in colon adenocarcinomas, inhibits proliferation and tumorigenesis of colon cancer cells.
|
Cancer Res
|
2004
|
1.38
|
|
14
|
EphB2 as a therapeutic antibody drug target for the treatment of colorectal cancer.
|
Cancer Res
|
2004
|
1.25
|
|
15
|
Inhibition of epithelial ductal branching in the prostate by sonic hedgehog is indirectly mediated by stromal cells.
|
J Biol Chem
|
2003
|
1.25
|
|
16
|
Antibody-drug conjugates targeted to CD79 for the treatment of non-Hodgkin lymphoma.
|
Blood
|
2007
|
1.11
|
|
17
|
Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis.
|
Magn Reson Med
|
2010
|
1.10
|
|
18
|
Cooperation of the proapoptotic receptor agonist rhApo2L/TRAIL with the CD20 antibody rituximab against non-Hodgkin lymphoma xenografts.
|
Blood
|
2007
|
1.09
|
|
19
|
MAGI-1: a widely expressed, alternatively spliced tight junction protein.
|
Exp Cell Res
|
2002
|
1.08
|
|
20
|
Preclinical evaluation of carcinoembryonic cell adhesion molecule (CEACAM) 6 as potential therapy target for pancreatic adenocarcinoma.
|
J Pathol
|
2009
|
1.02
|
|
21
|
Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.
|
Sci Transl Med
|
2013
|
1.01
|
|
22
|
Armed antibodies targeting the mucin repeats of the ovarian cancer antigen, MUC16, are highly efficacious in animal tumor models.
|
Cancer Res
|
2007
|
0.98
|
|
23
|
Antixenograft tumor activity of a humanized anti-insulin-like growth factor-I receptor monoclonal antibody is associated with decreased AKT activation and glucose uptake.
|
Mol Cancer Ther
|
2008
|
0.98
|
|
24
|
Quantification of viable tumor microvascular characteristics by multispectral analysis.
|
Magn Reson Med
|
2008
|
0.90
|
|
25
|
Effect of immune complex formation on the distribution of a novel antibody to the ovarian tumor antigen CA125.
|
Drug Metab Dispos
|
2010
|
0.83
|
|
26
|
Dose dependent pharmacokinetics, tissue distribution, and anti-tumor efficacy of a humanized monoclonal antibody against DLL4 in mice.
|
MAbs
|
2014
|
0.79
|
|
27
|
Erratum to: Ungersma SE, Pacheco G, Ho C, Yee SF, Ross J, van Bruggen N, Peale FV Jr, Ross S, Carano RA. Vessel imaging with viable tumor analysis for quantification of tumor angiogenesis. Magn Reson Med 2010;63:1637–1647.
|
Magn Reson Med
|
2011
|
0.78
|
|
28
|
Mapping in vivo tumor oxygenation within viable tumor by 19F-MRI and multispectral analysis.
|
Neoplasia
|
2013
|
0.78
|